Marinomed Biotech AG · VIE:MARI

Marinomed Biotech — Investor Presentation (April 2020)

10 slides from Marinomed Biotech's investor presentation, April 2020

  1. Slide 1: The basis for antiviral therapies

    The basis for antiviral therapies

  2. Slide 2: Company highlights

    Company highlights Innovative biopharmaceutical company focused on respiratory, allergy and ophthalmic OTC and Rx therapies Established biopharmaceutical company with a global presence • Unique, asset-light business model with significant growth potential 1 • Significant pipeline with multiple, deri

  3. Slide 3: Paradigm today

    Paradigm today There is no broad anti-viral treatment or vaccination against more than 200 different respiratory virus strains: • Coronavirus • Rhinovirus • Parainfluenza virus • Metapneumovirus • Respiratory syncytial virus • Influenza virus • Adenovirus These viruses cause or worsen important dise

  4. Slide 4: Virus associated indications

    Virus associated indications direct indirect Influenza Allergic Common cold rhinitis Sore throat Asthma RSV in pre- COPD mature infants Lung transplantation Indirect indications means medical conditions that are potentially worsened due to respiratory viral infections, such as asthma, allergic rhini

  5. Slide 5: Carragelose, the basis for antiviral therapies

    Carragelose®, the basis for antiviral therapies Technology platform for developing therapies targeting over 200 respiratory viral strains Based on iota-carrageenan polymers derived from red seaweed with physical mode of action A broadly active anti-viral compound for respiratory diseases Clinical pr

  6. Slide 6: Unique mode of action

    Unique mode of action Carragelose® blocks viral attachment to cells via an unspecific physical mechanism Preservative- and Carragelose creates Clotted viruses leave Cold viruses bind to Colds are caused by sugar-free. Can be a protective layer the body via the the surfaces of the more than 200 used

  7. Slide 7: Clinically validated

    Clinically validated Efficacy of Carragelose® platform has been clinically proven in children and adults à clinically proven to reduce cold symptoms and duration 3 Double-blind, placebo-controlled clinical trials in a natural setting conducted with Carragelose 450 Patients enrolled of which >150 chi

  8. Slide 8: Carragelose portfolio overview

    Carragelose® portfolio overview Six products already on the market, more to be developed 1 Nasal products • Anti-viral nasal spray • Anti-viral kids nasal spray Launched • Anti-viral cold/flu nasal spray 1 • Anti-viral decongestant nasal spray • Anti-viral Carragelose® -Xylometazoline combination La

  9. Slide 9: Excellent traction with established brands

    Excellent traction with established brands Carragelose® products are partnered with strong global partners Marinomed’s partners (Multiple) (Multiple) (Canada) (DE) (AUS/NZ) (AT) (Nordics) (HU) (Baltics) (GR) (CH) Partnered Not partnered yet Carragelose® products generated approximately €30m in total

  10. Slide 10: The basis for antiviral therapies Contact BD&L

    The basis for antiviral therapies Contact BD&L renate.moser@marinomed.com www.marinomed.com

Marinomed Biotech — Investor Presentation (April 2020) on 6ix